067630.KQ

HLB Life Science Co., Ltd. [067630.KQ] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

067630.KQ Stock Summary

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

Earnings are expected to fall -100% next year

Profit margins (-0.39%) are lower than the previous year (-0.06%)

Top 10 Correlated ETFs

067630.KQ

Top 10 Correlated Stocks

067630.KQ

In the News

067630.KQ Financial details

Company Rating

Buy

Market Cap

1739.11B

Income

-5.98B

Revenue

97.99B

Book val./share

2267.55

Cash/share

763.02

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

10 May 2024

P/E

-22.81

Forward P/E

PEG

2.56

P/S

8.83

P/B

4.48

P/C

21.32

P/FCF

-23.4

Quick Ratio

2.15

Current Ratio

2.63

Debt / Equity

0.72

LT Debt / Equity

0.22

EPS (TTM)

-58.74

EPS next Y

EPS next Q

EPS this Y

-89.06%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

-2.98%

Revenue Q/Q

7.81%

EPS Q/Q

-139.55%

SMA20

-8.67%

SMA50

23.23%

SMA100

80.77%

Inst Own

Inst Trans

ROA

-11%

ROE

-18%

ROC

-0.06%

Gross Margin

-2%

Oper. Margin

-20%

Profit Margin

-39%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

8260.0-25000.0

52W High

-34.92%

52W Low

+96.97%

RSI

Rel Volume

0.22

Avg Volume

4.23M

Volume

931.65K

Perf Week

2.33%

Perf Month

11.67%

Perf Quarter

80.98%

Perf Half Y

71.99%

Beta

0.462495

Volatility

300.62%, 2501.62%

Prev Close

-2.57%

Price

16270

Change

-2.22%

067630.KQ Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.23K	927.21	538.47	986.34	962.77
Net income per share	80.81	-563.59	-494.76	-537.56	-58.79
Operating cash flow per share	-133.12	20.3	-141.77	-294.58	-98.41
Free cash flow per share	-299.52	-189.88	-168.04	-410	-309.87
Cash per share	1.89K	1.6K	1.41K	1.3K	763.03
Book value per share	3.59K	2.9K	2.48K	2.32K	2.27K
Tangible book value per share	2.56K	2.11K	1.85K	1.22K	1.72K
Share holders equity per share	3.59K	2.9K	2.48K	2.32K	2.27K
Interest debt per share	208.13	133.54	54.6	1.55K	1.85K
Market cap	1605.28B	1707.81B	1236.84B	1039.99B	1164.37B
Enterprise value	1580.48B	1682.04B	1210.2B	1156.49B	1314.17B
P/E ratio	213.46	-30.61	-25.16	-19.16	-194.6
Price to sales ratio	14.08	18.6	23.12	10.44	11.88
POCF ratio	-129.59	849.64	-87.82	-34.96	-116.25
PFCF ratio	-57.59	-90.85	-74.09	-25.12	-36.92
P/B Ratio	4.81	5.95	5.02	4.43	5.04
PTB ratio	4.81	5.95	5.02	4.43	5.04
EV to sales	13.86	18.32	22.62	11.61	13.41
Enterprise value over EBITDA	-454.77	-260.54	-74.43	-77.21	-73.76
EV to operating cash flow	-127.58	836.82	-85.93	-38.88	-131.21
EV to free cash flow	-56.7	-89.48	-72.49	-27.94	-41.67
Earnings yield	0	-0.03	-0.04	-0.05	-0.01
Free cash flow yield	-0.02	-0.01	-0.01	-0.04	-0.03
Debt to equity	0.04	0.04	0.02	0.62	0.72
Debt to assets	0.03	0.03	0.02	0.36	0.39
Net debt to EBITDA	7.13	3.99	1.64	-7.78	-8.41
Current ratio	5.61	10.15	11.59	6	1.09
Interest coverage	-0.7	-3.8	-14.59	-2.02	-1.18
Income quality	-1.65	-0.04	0.29	0.55	1.67
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	-0.01	0	-0.26
Sales general and administrative to revenue	0	0.01	0.01	0.01	0.01
Research and developement to revenue	0.01	0.02	0.07	0.04	0.06
Intangibles to total assets	0.24	0.24	0.23	0.28	0.13
Capex to operating cash flow	1.25	-10.35	0.19	0.39	2.15
Capex to revenue	-0.14	-0.23	-0.05	-0.12	-0.22
Capex to depreciation	-8.14	-13.32	-1.26	-2.34	-2.8
Stock based compensation to revenue	0	0	0	0	0
Graham number	2.55K	6.06K	5.25K	5.3K	1.73K
ROIC	-0.01	-0.03	-0.07	-0.05	-0.06
Return on tangible assets	0.02	-0.23	-0.24	-0.18	-0.02
Graham Net	1.5K	1.36K	1.29K	-252.18	-983.58
Working capital	183.82B	163.46B	143.29B	133.99B	11.59B
Tangible asset value	238.07B	208.51B	183.8B	122.71B	175.41B
Net current asset value	153.16B	141.88B	132.63B	-14.95B	-45.24B
Invested capital	0.04	0.04	0.02	0.62	0.72
Average receivables	36.13B	30.26B	17.28B	16.27B	16.85B
Average payables	24.77B	16.14B	7.91B	9.83B	7.27B
Average inventory	6.5B	4.62B	1.93B	6.32B	8.07B
Days sales outstanding	130.12	79.01	100.2	65.42	59.02
Days payables outstanding	90.4	22.41	62.75	32.88	18.56
Days of inventory on hand	24.18	8.41	10.8	38.08	18.95
Receivables turnover	2.81	4.62	3.64	5.58	6.18
Payables turnover	4.04	16.29	5.82	11.1	19.66
Inventory turnover	15.09	43.4	33.8	9.58	19.27
ROE	0.02	-0.19	-0.2	-0.23	-0.03
Capex per share	-166.41	-210.18	-26.27	-115.42	-211.46

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	270.15	306.34	210.57	214.62	231.38
Net income per share	-609.29	134.26	-96.1	-160.29	63.39
Operating cash flow per share	-110.07	34.89	-53.21	-38.25	-41.82
Free cash flow per share	-165.08	0.26	-93.78	-84.44	-131.92
Cash per share	1.29K	1.5K	426.63	708.56	763.02
Book value per share	2.31K	2.44K	2.33K	2.21K	2.27K
Tangible book value per share	1.21K	1.56K	1.45K	1.31K	1.72K
Share holders equity per share	2.31K	2.44K	2.33K	2.21K	2.27K
Interest debt per share	1.49K	1.54K	1.58K	1.71K	1.74K
Market cap	1047.66B	1109.95B	1032.94B	933.34B	1164.39B
Enterprise value	1164.16B	1231.63B	1156.62B	1077.58B	1314.2B
P/E ratio	-4.23	20.31	-26.4	-14.3	45.11
Price to sales ratio	38.13	35.61	48.2	42.73	49.44
POCF ratio	-93.58	312.74	-190.74	-239.74	-273.54
PFCF ratio	-62.4	41.8K	-108.24	-108.59	-86.72
P/B Ratio	4.46	4.47	4.36	4.16	5.05
PTB ratio	4.46	4.47	4.36	4.16	5.05
EV to sales	42.37	39.52	53.97	49.33	55.8
Enterprise value over EBITDA	-180.43	-1.32K	-251.33	-239.96	-190.38
EV to operating cash flow	-103.98	347.02	-213.58	-276.79	-308.74
EV to free cash flow	-69.33	46.38K	-121.2	-125.38	-97.88
Earnings yield	-0.06	0.01	-0.01	-0.02	0.01
Free cash flow yield	-0.02	0	-0.01	-0.01	-0.01
Debt to equity	0.62	0.61	0.66	0.74	0.72
Debt to assets	0.36	0.35	0.37	0.4	0.39
Net debt to EBITDA	-18.06	-130.69	-26.87	-32.12	-21.7
Current ratio	6	6.53	2.69	3	1.09
Interest coverage	-1.87	-0.58	-1.25	-0.92	-0.8
Income quality	0.18	0.26	0.55	0.24	-0.66
Dividend Yield	0.09	0	0	0	0
Payout ratio	-1.58	0.05	-0.01	0	0
Sales general and administrative to revenue	0.01	0.01	0.02	0.02	0
Research and developement to revenue	0.06	0.03	0.06	0.04	0.1
Intangibles to total assets	0.28	0.21	0.22	0.22	0.13
Capex to operating cash flow	0.5	-0.99	0.76	1.21	2.15
Capex to revenue	-0.2	-0.11	-0.19	-0.22	-0.39
Capex to depreciation	-2.5	-1.8	-2.01	-2.43	-5.23
Stock based compensation to revenue	0	0	0	0	0
Graham number	5.62K	2.72K	2.24K	2.82K	1.8K
ROIC	-0.02	-0.01	-0.02	-0.02	-0.02
Return on tangible assets	-0.21	0.04	-0.03	-0.05	0.02
Graham Net	-250.33	-125.04	-1.2K	-1.02K	-983.56
Working capital	133.99B	146.9B	40.53B	64.48B	11.59B
Tangible asset value	122.71B	158.7B	147.81B	133.41B	175.41B
Net current asset value	-14.95B	-3.4B	-112.3B	-92.87B	-45.24B
Invested capital	0.62	0.61	0.66	0.74	0.72
Average receivables	19.52B	14.36B	11.02B	12.03B	14.36B
Average payables	10.28B	8.57B	7.27B	6.76B	5.95B
Average inventory	11.73B	9.28B	7.01B	7B	6.47B
Days sales outstanding	58.46	31.37	46.97	53.02	60.55
Days payables outstanding	26.59	23.69	26.44	25.91	18.22
Days of inventory on hand	30.79	23.52	24.64	29.49	18.6
Receivables turnover	1.54	2.87	1.92	1.7	1.49
Payables turnover	3.39	3.8	3.4	3.47	4.94
Inventory turnover	2.92	3.83	3.65	3.05	4.84
ROE	-0.26	0.05	-0.04	-0.07	0.03
Capex per share	-55	-34.62	-40.56	-46.19	-90.09

067630.KQ Frequently Asked Questions

What is HLB Life Science Co., Ltd. stock symbol ?

HLB Life Science Co., Ltd. is a KR stock and trading under the symbol 067630.KQ

What is HLB Life Science Co., Ltd. stock quote today ?

HLB Life Science Co., Ltd. stock price is $16270 today.

Is HLB Life Science Co., Ltd. stock public?

Yes, HLB Life Science Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 4.23M
Market Capitalization 1739.11B
Employee 26
CEO Sung-Bo Sim
Headquarters Hwaseong-si,KR
IPO Date 2008-11-25
Website https://www.hlb-ls.com

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/Ã-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea.